#	Pagina
attuale pagina	/open-h2020/projects/217596/index.html

Opendata, web and dolomites

QuickMIC

QuickMIC™ - an ultra-rapid diagnostic system for Antibiotic Susceptibility Testing (AST)

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

QuickMIC project word cloud

Explore the words cloud of the QuickMIC project. It provides you a very rough idea of what is the project "QuickMIC" about.

survival combining rates continuous misuse patients guide blood patient antibiotic ivd innovation marking worldwide diagnostic additionally quicker globally detection bacterial samples tested decrease unmet diagnosis ultra survive contribution usually continued price microfluidics amr effort fastest significantly death doctors quickmic golden competitiveness treatment sepsis more plan susceptibility treating fighting tool infection time unsuccessful patented hours ed empirically escalating ast commercializing successful competitors standard antibiotics contributes reduce people rapid commercialisation trade besides direct 48 clinical treat approx antimicrobial market appropriate alternative million spectrum image resistance empirical business disease ce platform 2019 improvement gradientech

Project "QuickMIC" data sheet

The following table provides information about the project.

Coordinator	GRADIENTECH AB Organization address address: UPPSALA SCIENCE PARK city: UPPSALA postcode: 75183 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Sweden [SE]
Project website	https://gradientech.se/funding-horizon-2020-sme-instrument/
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-1
Funding Scheme	SME-1
Starting year	2018
Duration (year-month-day)	from 2018-04-01 to 2018-09-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	GRADIENTECH AB GRADIENTECH AB Organization address address: UPPSALA SCIENCE PARK city: UPPSALA postcode: 75183 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (UPPSALA)	coordinator	50˙000.00

Map

Project objective

The aim of the project is to bring QuickMIC™, an ultra-rapid diagnostic tool for Antibiotic Susceptibility Testing (AST) to the market and clinical practice. AST is usually carried out to determine which antibiotic will be the most appropriate in treating a bacterial infection in a particular patient. Sepsis is the major cause of death as a result of an infection today. It affects approx. 30 million of people every year worldwide. About 20 % of the patients do not survive the disease. Currently, it can take up to 48 hours for the current golden standard AST method to produce reliable diagnostic results. Therefore, doctors empirically treat sepsis patients with wide-spectrum antibiotics while the blood samples are being tested. The globally escalating antimicrobial resistance (AMR) has resulted in empirical treatment being unsuccessful more and more often. Misuse of antibiotics additionally contributes to increasing resistance. The improvement of survival rates in sepsis and the decrease in AMR will only be possible with access to a quicker AST tool. To address this unmet clinical need, Gradientech is developing an ultra-rapid AST system, QuickMIC™, based on a patented technology platform. By combining i) advanced microfluidics and ii) continuous image detection and analysis, QuickMIC™ can reduce the time of an AST to two hours. Besides being the fastest AST under development, QuickMIC™ is also a low-price alternative compared to its direct competitors. By commercializing QuickMIC™, Gradientech will make an important contribution to fighting AMR in Europe. Moreover, we will significantly improve the diagnosis and treatment of sepsis. A continued development of QuickMIC™ will result in a CE-IVD marking by early 2019. In the Phase 1 project, we will develop a business plan that will guide the future clinical studies and commercialisation activities. If successful, the overall innovation effort will take Gradientech to a new level of competitiveness and growth.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "QUICKMIC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "QUICKMIC" are provided by the European Opendata Portal: CORDIS opendata.